

NOTICE TO RECIPIENTS - LIMITED USE LICENSE

Use of the Tetracycline controllable expression technology (the "Tet Technology") is covered under U.S. patents 8,383,364, RE49,583, 9,181,556, European Patents EP 1954811 and 2352833 and equivalents in other territories which are proprietary to TET Systems GmbH & Co.KG ("TET Systems").

Not-for-profit and academic research institutions are granted an automatic cost-free license with the receipt of this material to use the Tet Technology only for internal, academic research purposes, which license specifically excludes the right to sell the Tet Technology or its component parts to third parties. Transfer of the Tet Technology or its component parts to other not-for-profit organizations requires a NOTICE TO RECIPIENT to be requested from TET Systems.

Academic and not-for-profit organizations whose research using the Tet Technology is sponsored by for-profit organizations, which shall receive ownership to any data or results stemming from the sponsored research, shall need a commercial license agreement from TET Systems to use the Tet Technology.

For-profit entities are required to conclude a license with TET Systems prior to obtain component parts of the Tet Technology or using them for any purpose.

In accepting these terms, all users acknowledge that the Tet Technology is experimental in nature, and that the material will not be used in humans. TET Systems makes no warranties, express or implied of any kind, and hereby disclaims all warranties, representations or guarantees of any kind as to the Tet Technology, patents, or products.

For license information, please contact:

TET Systems GmbH & Co. KG

Attn.: Managing Director

Vangerowstrasse 20

69115 Heidelberg, Germany

Tel: +49 6221 5880400

Fax: +49 6221 5880404

email: info@tet-systems.com

or use the electronic licensing request form via

<https://www.tetsystems.com/licensing/#licensing-questionnaire>